The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years ...

The FDA has approved Blujepa (gepotidacin) for the treatment of female patients 12 years of age and older weighing at least 40kg with uncomplicated UTI.

Up to 30% of acute kidney injury (AKI) survivors require dialysis and personalized care after discharge from the hospital.

Midlife cardiometabolic profiles were differentially associated with risk for early- and late-onset dementia regardless of genetic predisposition.

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

Severity of cardiometabolic comorbidity burden affects risk for all-cause hospitalization in patients with heart failure.

The Trump administration will lay off 10,000 workers at the US Department of Health and Human Services as part of a major reorganization.

The FDA has approved Egrifta WR, a concentrated formulation (F8) of tesamorelin, for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.

HealthDay News — Open-label placebo (OLP) provided with a treatment rationale is effective and safe for premenstrual syndrome (PMS), according to a study published online March 25 in BMJ ...

Lonapegsomatropin demonstrated efficacy outcomes superior to daily somatropin in treatment of pediatric growth hormone deficiency.

The U.S. Centers for Disease Control and Prevention (CDC) is facing major changes, with five senior leaders stepping down.

Graves disease had similar presentation but a more severe clinical course when isolated than when part of autoimmune polyglandular syndrome.